Author: admin

  • Sheila Gilmore – 2014 Parliamentary Question to the Department for Work and Pensions

    Sheila Gilmore – 2014 Parliamentary Question to the Department for Work and Pensions

    The below Parliamentary question was asked by Sheila Gilmore on 2014-06-05.

    To ask the Secretary of State for Work and Pensions, when the Help and Support for Separated Families Co-ordinated Telephone Network started full operation; and which organisations are taking part.

    Steve Webb

    The Help and Support for Separated Families telephone network began full operation in March 2014 and the participating organisations are:

    Family Lives;

    Relate;

    Wikivorce; and

    The National Youth Advocacy Service.

    £344k of awards have been made for the co-ordinated telephony network. £344k is the maximum amount payable under the terms of the grant for the period to 31st May 2014. This covers both actual invoices paid to date and amounts not yet billed by suppliers. The evaluation of the telephony network will be carried out in-house.

  • Sheila Gilmore – 2014 Parliamentary Question to the Department for Work and Pensions

    Sheila Gilmore – 2014 Parliamentary Question to the Department for Work and Pensions

    The below Parliamentary question was asked by Sheila Gilmore on 2014-06-05.

    To ask the Secretary of State for Work and Pensions, what the cost to his Department has been of implementing and evaluating the Help and Support for Separated Families Co-ordinated Telephone Network to date; and what estimate he has made of the future costs of that initiative.

    Steve Webb

    The Help and Support for Separated Families telephone network began full operation in March 2014 and the participating organisations are:

    Family Lives;

    Relate;

    Wikivorce; and

    The National Youth Advocacy Service.

    £344k of awards have been made for the co-ordinated telephony network. £344k is the maximum amount payable under the terms of the grant for the period to 31st May 2014. This covers both actual invoices paid to date and amounts not yet billed by suppliers. The evaluation of the telephony network will be carried out in-house.

  • Sheila Gilmore – 2014 Parliamentary Question to the Department for Work and Pensions

    Sheila Gilmore – 2014 Parliamentary Question to the Department for Work and Pensions

    The below Parliamentary question was asked by Sheila Gilmore on 2014-06-05.

    To ask the Secretary of State for Work and Pensions, what funding has been paid from the Help and Support for Separated Families (HSSF) Innovation Fund to each of the HSSF projects which signed contracts for delivery in April 2013.

    Steve Webb

    All Innovation Fund projects deliver different services and have different timescales. Their agreed payment schedules are considered commercially sensitive and cannot be shared at this time.

  • Oliver Colvile – 2014 Parliamentary Question to the Department for Business, Innovation and Skills

    Oliver Colvile – 2014 Parliamentary Question to the Department for Business, Innovation and Skills

    The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

    To ask the Secretary of State for Business, Innovation and Skills, what specialist one-to-one study skills support will be available for students with specific learning difficulties following the review of the disabled students allowance; and who will provide that support.

    Mr David Willetts

    Discussions are underway with stakeholders, including those who specialise in supporting students with Specific Learning Difficulties. This will help determine how specialist one-to-one support will be delivered in the future and where the responsibility for funding such support will fall.

    I will not make a final decision on this matter until I have considered the necessary Equality Analysis, which is in preparation, and will take account of any relevant evidence provided by stakeholders.

  • Oliver Colvile – 2014 Parliamentary Question to the Department of Health

    Oliver Colvile – 2014 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

    To ask the Secretary of State for Health, what assessment he has made of the changes in the level of access to prostate cancer treatments since 2010.

    Jane Ellison

    The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.

    Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.

    The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.

    National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.

    Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.

    Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.

    The Government’s Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.

  • Oliver Colvile – 2014 Parliamentary Question to the Cabinet Office

    Oliver Colvile – 2014 Parliamentary Question to the Cabinet Office

    The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

    To ask the Minister for the Cabinet Office, how many people died from prostate cancer in (a) Plymouth, Sutton and Devonport constituency and (b) England in each of the last five years.

    Mr Nick Hurd

    The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.

  • Oliver Colvile – 2014 Parliamentary Question to the Department of Health

    Oliver Colvile – 2014 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

    To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.

    Jane Ellison

    The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.

    Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.

    The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.

    National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.

    Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.

    Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.

    The Government’s Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.

  • Oliver Colvile – 2014 Parliamentary Question to the Department of Health

    Oliver Colvile – 2014 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

    To ask the Secretary of State for Health, what assessment his Department has made of outcomes for men with advanced prostate cancer.

    Jane Ellison

    The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.

    Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.

    The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.

    National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.

    Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.

    Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.

    The Government’s Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.

  • Mary Creagh – 2014 Parliamentary Question to the Department for Transport

    Mary Creagh – 2014 Parliamentary Question to the Department for Transport

    The below Parliamentary question was asked by Mary Creagh on 2014-06-05.

    To ask the Secretary of State for Transport, if he will publish a breakdown by firm of expenditure by his Department on (a) consultants and (b) consultancy firms in each of the last four years.

    Stephen Hammond

    Information requested will be deposited in the library and provides the spend details per financial year for the period 2010 to 2014.

  • Debbie Abrahams – 2014 Parliamentary Question to the Department for Transport

    Debbie Abrahams – 2014 Parliamentary Question to the Department for Transport

    The below Parliamentary question was asked by Debbie Abrahams on 2014-06-05.

    To ask the Secretary of State for Transport, what recent discussions he has had with train operating companies in Greater Manchester on last minute reductions in train configurations.

    Stephen Hammond

    The franchise agreement between the Government and each individual train operator includes benchmarks in key performance areas. The Department monitors each train operator’s overall performance against these areas every four weeks and there are clear actions set out in the franchise agreement should performance drop below what is expected. This regular monitoring includes monthly meetings with their senior management where performance figures are scrutinised and challenged.

    Short-forming (last minute reductions in train configurations) is included in this monitoring, and therefore in the monthly meetings. It is the train operator that decides on whether a service is to be short-formed, and if contractual benchmark figures are breached, the Department does take enforcement action.

    Some services in Greater Manchester are sponsored and specified by Transport for Greater Manchester, who also monitor the performance of the operators concerned.